Repligen Corporation (RGEN) is a publicly traded company in the Healthcare sector, operating within the Medical - Instruments & Supplies industry. The company is headquartered in Waltham, MA, United States. The current CEO is Olivier Loeillot.
RGEN has IPO date of 1986-04-29, 1,778 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $7.38B.
Repligen Corporation is a global bioprocessing technology company that develops and commercializes systems and products for biological drug manufacturing. The company serves biopharmaceutical, life sciences, and diagnostics customers across North America, Europe, and Asia Pacific with a comprehensive portfolio including Protein A affinity chromatography resins, pre-packed chromatography columns, cell culture growth factors, filtration systems, and process analytics solutions. Its product lines—such as OPUS chromatography columns, XCell filtration systems, and SoloVPE spectroscopy platforms—support critical stages of biologic drug purification, concentration, and quality control. Repligen was founded in 1981 and is headquartered in Waltham, Massachusetts.
